Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor

被引:72
|
作者
Creamer, D
Allen, M
Jaggar, R
Stevens, R
Bicknell, R
Barker, J
机构
[1] Kings Coll Hosp London, St Johns Inst Dermatol, St Thomas Hosp, London SE5 9RS, England
[2] Imperial Canc Res Fund, Inst Mol Med, Mol Angiogenesis Grp, Oxford, England
[3] St Thomas Hosp, Dept Rheumatol, London, England
关键词
D O I
10.1001/archderm.138.6.791
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Severe forms of psoriasis can be complicated by systemic microvascular hyper-permeability. Vascular endothelial growth factor (VEGF) possesses potent vascular permeability activity. We suggest that VEGF enters the systemic circulation and acts on microvessels to mediate hyperpermeability. Objectives: To quantify renal microvascular permeability and circulating VEGF concentration in severe psoriasis, and to investigate the relationship between plasma VEGF concentration and skin and joint involvement. Design: Inception cohort studies of patients with generalized pustular psoriasis and plaque psoriasis. Setting: St John's Institute of Dermatology, London, England. Patients: Twenty-two patients (15 men and 7 women) with moderate and severe psoriasis were recruited (age range, 29-77 years; mean age, 47 years); 5 had generalized pustular psoriasis, 2 had erythrodermic psoriasis, and 15 had moderate-severe plaque psoriasis. An age- and sex-matched control group of 17 individuals (10 men and 7 women) was recruited (age range, 29-69 years; mean age, 42 years). Results: There was pathological proteinuria in patients with relapsing generalized pustular psoriasis, (4-fold increase in urinary protein excretion rate in relapse compared with remission). In patients with moderate and severe psoriasis, mean plasma VEGF concentration during relapse was approximately 2.5 times greater than during remission (mean VEGF(relapse)=257 pg/mL; mean VEGF(remission)=103 pg/mL; P<.01). There was a correlation between extent of skin involvement and plasma VEGF level (mean VEGF(severe) (psoriasis) = 365 pg/ml; mean VEGF(moderate psoriasis) = 149 pg/mL; P=.03). There was a correlation between presence of psoriatic arthritis and plasma VEGF level (mean relapse VEGF(arthritis)=277 pg/mL; mean relapse VEGF(nonarthritis),= 103.5 pg/mL; P=.03). Conclusions: Generalized pustular psoriasis is accompanied by pathological proteinuria and elevated plasma VEGF levels. Plasma VEGF concentration is significantly elevated in patients with extensive skin and joint involvement and may act on renal microvasculature to induce hyperpermeability.
引用
收藏
页码:791 / 796
页数:6
相关论文
共 50 条
  • [31] Circulating and exhaled vascular endothelial growth factor in asthmatic pregnancy
    Bikov, Andras
    Bohacs, Aniko
    Eszes, Noemi
    Weiszhar, Zsoka
    Ivancso, Istvan
    Muller, Veronika
    Rigo, Janos
    Losonczy, Gyorgy
    Tamasi, Lilla
    Horvath, Ildiko
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [32] Circulating vascular endothelial growth factor and the risk of cardiovascular events
    Kaess, Bernhard M.
    Preis, Sarah R.
    Beiser, Alexa
    Sawyer, Douglas B.
    Chen, Tai C.
    Seshadri, Sudha
    Vasan, Ramachandran S.
    HEART, 2016, 102 (23) : 1898 - 1901
  • [33] Circulating vascular endothelial growth factor in cutaneous malignant melanoma
    Pelletier, F
    Bermont, L
    Puzenat, E
    Blanc, D
    Mougin, C
    Laurent, R
    Humbert, P
    Aubin, F
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 123 (06) : A107 - A107
  • [34] Elevated circulating vascular endothelial growth factor in erythroderma.
    Creamer, D
    Allen, MH
    Groves, RW
    Barker, JNWN
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1996, 107 (03) : 105 - 105
  • [35] Circulating vascular endothelial growth factor in patients with colorectal cancer
    Fujisaki, K
    Mitsuyama, K
    Toyonaga, A
    Matsuo, K
    Tanikawa, K
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1998, 93 (02): : 249 - 252
  • [36] Genetic interaction between placental growth factor and vascular endothelial growth factor A in psoriasis
    Young, H. S.
    Kamaly-Asl, I. D.
    Laws, P. M.
    Pemberton, P.
    Griffiths, C. E. M.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2020, 45 (03) : 302 - 308
  • [37] Changes in circulating levels of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 after carotid endarterectomy
    Papalambros, E
    Georgopoulos, S
    Sigala, F
    Vourliotakis, G
    Chrisostomidis, G
    Venetsanou, K
    Hadjoulis, G
    Felekouras, E
    Bastounis, E
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2004, 14 (01) : 133 - 136
  • [38] Circulating Levels of Vascular Endothelial Growth Factor and Basic Fibroblastic Growth Factor in Infantile Hemangioma Versus Vascular Malformations
    El-Raggal, Nehal M.
    El-Farrash, Rania A.
    Saad, Abeer A.
    Attia, Enas A. S.
    Saafan, Hatem A.
    Shaaban, Ibrahim S.
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2018, 24 (04) : 663 - 668
  • [39] Vascular Endothelial Growth Factor in Systemic Capillary Leak Syndrome
    Lesterhuis, Willem Joost
    Rennings, Alexander J.
    Leenders, William P.
    Nooteboom, Arjan
    Punt, Cornelis J.
    Sweep, Fred C.
    Pickkers, Peter
    Geurts-Moespot, Anneke
    Van Laarhoven, Hanneke W.
    Van der Vlag, Johan
    Berden, Jo H.
    Postma, Cor T.
    Van der Meer, Jos W.
    AMERICAN JOURNAL OF MEDICINE, 2009, 122 (06): : E5 - E7
  • [40] Pigment epithelium-derived factor inhibits vascular endothelial growth factor-induced vascular hyperpermeability both in vitro and in vivo
    Yamagishi, S.
    Abe, R.
    Jinnouchi, Y.
    Matsui, T.
    Imaizumi, T.
    Inoue, H.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2007, 35 (06) : 896 - 899